Wikidata

(Q40126331)

English

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

scientific article published on 5 February 2008

In more languages

Statements

title
Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer (English)
1 reference
stated in
Europe PubMed Central
PubMed ID
18255187
retrieved
17 September 2017
author
Karen Kelly
object named as
Karen Kelly
series ordinal
4
0 references
author name string
F Anthony Greco
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
18255187
retrieved
17 September 2017
Philip Bonomi
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed ID
18255187
retrieved
17 September 2017
Jeffrey Crawford
series ordinal
3
1 reference
stated in
Europe PubMed Central
PubMed ID
18255187
retrieved
17 September 2017
Wendy Halpern
series ordinal
6
1 reference
stated in
Europe PubMed Central
PubMed ID
18255187
retrieved
17 September 2017
Larry Lo
series ordinal
7
1 reference
stated in
Europe PubMed Central
PubMed ID
18255187
retrieved
17 September 2017
Gilles Gallant
series ordinal
8
1 reference
stated in
Europe PubMed Central
PubMed ID
18255187
retrieved
17 September 2017
Jerry Klein
series ordinal
9
1 reference
stated in
Europe PubMed Central
PubMed ID
18255187
retrieved
17 September 2017
publication date
5 February 2008
1 reference
stated in
Europe PubMed Central
PubMed ID
18255187
retrieved
17 September 2017
page(s)
82-90
1 reference
stated in
Europe PubMed Central
PubMed ID
18255187
retrieved
17 September 2017

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q40126331&oldid=1966797367"